[ANAB] Anaptys: Jemperli Royalty Math and the Sagard Cash Crossover

Anaptys is now a company that lives on one drug it does not sell. Having spun off its biopharma programmes, everything left inside ANAB is the right to hold and manage dostarlimab, marketed by GSK as Jemperli, and to collect a contractual share of its sales[1]. The company is scheduled to report on 2026-09-23, covering the six-month transition period from 1 January 2026 to 30 June 2026, to be filed as a transition report on Form 10-KT following the change of fiscal year-end from 31 December to 30 June[2]. The last disclosed figures stop at the first quarter of 2026: collaboration revenue of $25.6 million against $27.8 million a year earlier, the decline caused by the absence of a $9.7 million Vanda licence recognition and partly offset by Jemperli royalties rising 44% from $17.2 million to $24.7 million[3], with $20.9 million of non-cash interest expense in the same quarter[4]. Management has published three sets of forward figures for the post-spin company: annualised operating expenses of less than $10 million and an EBIT margin above 95%[5]; roughly $140-$145 million of initial net cash and investments after the separation, together with an authorisation to repurchase up to $100.0 million of stock[6]; and the remaining ~$325 million of Sagard non-recourse monetisation to be paid down by the end of the second quarter of 2027[7]. The consensus Investing.com compiled on 16 August 2026 looks for revenue of $20.2 million and a loss of $0.13 per share for the quarter ended 30 June[8]; that estimate covers a single quarter while the company is filing a six-month report, so the periods do not line up and it cannot be read as a beat-or-miss line.

This disclosure can settle three things. First, whether the royalty line is a clean pass-through: GSK reported Jemperli net sales of $313 million (232 million pounds) in the first quarter of 2026, up more than 40% year over year[9], while the $24.6 million Anaptys recognised is almost exactly the contractual 8% first tier[10], so a report that shows six months of net sales alongside the royalty booked would let a reader check the arithmetic directly and see how much of it is a true-up of an earlier estimate. Second, where the Sagard paydown stands: Sagard had received $249.3 million of the $600.0 million cap at 31 March 2026[11], and until that cap is reached every dollar of royalty cash belongs to Sagard while the company's own costs, legal fees and buybacks come out of the balance sheet, which makes whether the liability actually fell over these six months, and whether the company still stands behind the end-of-Q2-2027 date, more consequential than the size of the royalty itself. Third, the post-separation cost base: general and administrative expense was $26.2 million in the first quarter of 2026, which the company attributed mainly to separation legal costs, the ongoing GSK litigation and stock compensation for two departed officers[12], and this is the first window that offers any evidence on how much of that was one-off and how far the remaining run rate sits from the stated plan of less than $10 million a year.

Company Background and Business Structure

What Anaptys is today is the residue of twenty years of antibody research rather than the business it set out to build. The company was incorporated in Delaware in 2005 and built an antibody discovery platform in San Diego, out-licensing antibodies to partners while running its own clinical programmes[13]. Two of those licences became the company: in 2014 it granted Tesaro, later acquired by GSK, an exclusive licence to the anti-PD-1 antibody that became Jemperli, and an October 2020 amendment raised the royalty to a tiered 8% to 25% of worldwide net sales[10]; in January 2025 it licensed imsidolimab to Vanda Pharmaceuticals. On 20 April 2026 it completed the separation of its biopharma operations by means of a spin-off into a new public company, First Tracks Biotherapeutics (Nasdaq: TRAX), distributing one First Tracks share for every Anaptys share and sending rosnilimab, ANB033 and ANB101 with it[14]. What kept the Anaptys name and the ANAB ticker is a royalty holding company, and in May 2026 the board also moved the fiscal year-end to 30 June[2].

After the separation there is one business: holding and managing the rights to dostarlimab, including the Jemperli royalties arising from the agreements with Tesaro and GlaxoSmithKline and the imsidolimab royalties from the Vanda collaboration[15]. There is no research, no manufacturing, no salesforce and no inventory; management describes the operating model as fewer than about ten full-time equivalents engaged as contractors to support the essential functions of a public company, annualised operating expenses of less than $10 million and an EBIT margin above 95%[5]. The second royalty is still worth nothing: the separation agreement allocated every Vanda milestone to First Tracks and left Anaptys only a 10% royalty on future net sales[16], and imsidolimab in generalized pustular psoriasis has an FDA target action date of 12 December 2026 with no approved sales yet[17].

More importantly, the main royalty is itself encumbered. In October 2021 and again in May 2024 the company sold future Jemperli royalties and certain milestones to Sagard for $300.0 million in total, and in September 2022 it sold the Zejula royalty outright to DRI Healthcare Trust for $35.0 million[13]; those receipts are still recognised as revenue and then paid straight through to the purchasers until Sagard has received the $600.0 million cap[11]. Anaptys also remains the tenant of record on roughly 45,057 square feet at Wateridge Circle in San Diego, which it has sublet to First Tracks while staying responsible for rent and the other obligations under the master lease[18].

Financial History and Current Position

The financial history of Anaptys is the history of a company that spent heavily on research and was rescued by a royalty. Collaboration revenue rose from $17.2 million in 2023 to $91.3 million in 2024 and then to $234.6 million in 2025, while the operating loss ran at $164.4 million in 2023 and $114.9 million in 2024[13]. The 2025 revenue came from two sources: Jemperli royalty revenue of $96.0 million, up from $47.4 million in 2024 and $13.8 million in 2023[19]; and two sales milestones totalling $125.0 million recognised when Jemperli annual sales passed $750 million and then $1.0 billion, of which $75.0 million was retained by the company and the remaining $50.0 million was paid to Sagard[20]. That produced $47.9 million of operating income for the year, but after $81.6 million of non-cash interest expense[19] the year still ended in a $13.2 million net loss[13].

The most recent period with figures is the first quarter of 2026, which is also the last period that still contains First Tracks. Collaboration revenue was $25.6 million against $27.8 million a year earlier, the gap coming from the $9.7 million Vanda licence recognition booked in the prior-year quarter and partly offset by Jemperli royalties rising 44% from $17.2 million to $24.7 million[3]. Operating expenses totalled $60.2 million, split between $34.0 million of research and development and $26.2 million of general and administrative[12]; with $20.9 million of non-cash interest on top[4], the quarter produced a $52.9 million net loss, or $1.84 per share[3].

The balance sheet carries two numbers pulling against each other. Cash, cash equivalents and investments were $311.6 million at 31 December 2025 against $420.8 million a year earlier[13], and $286.5 million at 31 March 2026, although that figure was measured before the separation and the company states that its rights to payments under its collaboration agreements are its only committed external source of funds[21], against post-spin guidance of an initial ~$140-$145 million[6]. On the other side sits the liability created by selling future royalties: $263.7 million at 31 March 2026, of which $240.8 million relates to Jemperli[22], accreting non-cash interest at a 34.9% effective rate[23].

Operating Model

Revenue is a contractual percentage of somebody else's sales. GSK books worldwide Jemperli net sales and Anaptys applies the tiers set by the October 2020 amendment - 8% of net sales below $1.0 billion, 12% between $1.0 billion and $1.5 billion, 20% between $1.5 billion and $2.5 billion and 25% above $2.5 billion - to cumulative calendar-year sales, recognising the result as collaboration revenue with no cost of goods[10]. GSK reports sales to Anaptys one quarter in arrears, so each period's figure is an estimate trued up in the next[4]. Sales milestones sit on top as lumpy one-off revenue: $258.0 million had been recognised through 31 March 2026, with $15.0 million still tied to a European filing and approval in a second indication[24]. The second revenue line is still zero: the Vanda imsidolimab royalty is 10% of net sales[16], and the product is waiting on its 12 December 2026 FDA target action date[17].

With no cost of revenue, gross profit equals revenue and operating income is revenue less a near-fixed overhead. The model management describes is fewer than ten contractors and less than $10 million of annual expense, giving an EBIT margin above 95%[5]. No reported period demonstrates it yet: the first quarter of 2026 still carried $34.0 million of research and development and $26.2 million of general and administrative, all of it from the business that left on 20 April[12]. The item that has kept the company loss-making even in good years sits below operating income - non-cash interest expense on the royalty sale, $81.6 million in 2025[19] and $20.9 million in the first quarter of 2026[4], accrued at a 34.9% effective rate that is itself a function of management's own royalty forecast[23].

Revenue and cash are disconnected in this company, and will stay disconnected until the Sagard cap is reached. Recognised Jemperli royalties are swept straight to Sagard - $32.6 million in the first quarter of 2026 - reducing the liability rather than the bank balance[22]; Sagard had received $249.3 million of the $600.0 million cap at 31 March 2026[11], and the company expects the remainder to be paid down by the end of the second quarter of 2027, after which the royalty reverts to Anaptys[7]. Until then the company's cash comes from the balance sheet it kept, the interest it earns on it and the occasional retained milestone such as the $75.0 million received from GSK in December 2025[20]; its uses are the fixed overhead, the Chancery litigation and the $100.0 million repurchase authorisation that expires at the end of 2026[25].

Industry and Competitive Position

The right comparators for Anaptys today are royalty companies rather than drug developers. It is a single-asset royalty holder whose position in oncology is entirely derivative of GSK's: Jemperli is an anti-PD-1 antibody competing head-on with Merck's Keytruda, which Anaptys names as its biggest competitor while warning that Keytruda sales are expected to be materially hurt by biosimilar competition between 2028 and 2029[26]. Pricing, promotion, trial investment and geographic reach are all GSK's decisions and Anaptys simply receives a contractual percentage[10], with no vote on any of it, since the business it retained is defined as holding and managing rights[15].

Inside that structure the one lever the company still holds is legal. It is suing Tesaro in the Delaware Court of Chancery over exclusivity and commercially-reasonable-efforts duties in the collaboration agreement, and alleges that its parent GSK tortiously interfered with it[27], which is why a contract dispute matters more here than it normally would. On the record so far the money has kept flowing during the dispute: $258.0 million of milestones had been recognised under the GSK agreement through 31 March 2026[24]. The ceiling on this revenue line depends entirely on GSK's volume: the company states that it continues to expect more than $390 million of annualised Jemperli royalties as early as 2029 at GSK's peak sales guidance of more than $2.7 billion[28], which requires sales to climb into the 20% and 25% tiers[10].

Core Debates

Over the January-to-June 2026 transition period, does the Jemperli royalty Anaptys recognises simply equal GSK-reported Jemperli net sales multiplied by the contractual 8% first tier, and if not, is the gap currency, the annual tier reset, or a true-up of GSK's one-quarter-lag reporting?

The arithmetic matters because Anaptys no longer has a pipeline, a factory or a salesforce, so this one calculation is close to the entire income statement. In the first quarter of 2026 the company recognised $24.6 million of Jemperli royalty revenue[4] while GSK reported $313 million of Jemperli net sales for the same three months[9], which is almost exactly the contractual 8% first tier[10], and the company separately described those royalties as rising 44% from $17.2 million a year earlier[3]. The same arithmetic produced $96.0 million of royalty revenue for the whole of 2025, a figure that already includes the step up to the 12% tier once cumulative annual net sales passed $1.0 billion late in the year[19]. If the line really is a clean pass-through, the company can be read as a transparent map of one drug's commercial performance.

The equally defensible alternative is that it is not a clean pass-through at all. The company states that GSK reports sales to it on a one-quarter lag and that differences between actual and estimated royalties are adjusted in the following quarter, so a period can move on a true-up rather than on current demand[4]. The transition period is the first test of that distinction, because the fiscal year now ends on 30 June while the royalty tier still resets on the calendar year[2] - which means the January-to-June half almost certainly sits entirely in the 8% tier, with the 12% tier only reachable later in the calendar year, and the reporting period and the rate period no longer coincide.

Four things can be observed directly: whether the transition report discloses Jemperli net sales for the same months alongside the royalty it recognised, so the 8% calculation can be checked; how much of the period's revenue is a true-up of an earlier estimate; whether the company states where cumulative calendar-year net sales stood at 30 June 2026, which sets how soon the 12% tier applies in the second half; and whether currency is separated from volume, given that GSK books Jemperli in pounds sterling[9]. The falsifying observations are just as clear: royalty revenue rising while GSK reports flat or falling net sales for the same months; a prior-period royalty trued up by more than a tenth, showing the estimate rather than the sales drives the line; or an implied rate pointing to a tier other than 8% while calendar-year cumulative sales are still below $1.0 billion[10].

Anaptys sold the Jemperli royalty to Sagard under a cap that ends only when Sagard has received $600.0 million. Did the six-month transition period retire enough of the remaining balance to keep the company's stated end-of-Q2-2027 crossover date intact?

Until the cap is reached, Anaptys recognises the Jemperli royalty as revenue and then pays it straight to Sagard, so the income statement shows a royalty business while the cash statement shows none. Everything the company can do for shareholders before then has to be funded out of the balance sheet, which makes the date the sweep ends the single most consequential number in the company, and that date is set by how fast the remaining balance is retired rather than by how large the royalty looks. At 31 March 2026 Sagard had received $249.3 million of the $600.0 million threshold[11]; the company's own estimate was that roughly $275 million had accrued to Sagard through the first quarter, with about $325 million remaining to be paid down by the end of the second quarter of 2027[7].

The rollforward for the same period shows the curve is not travelling easily. In the first quarter $32.6 million of royalties and milestones was swept to Sagard against $20.9 million of non-cash interest accrued, so the Jemperli liability fell from $252.6 million to $240.8 million[22]. The alternative reading is that the schedule is fragile rather than conservative: the company's own footnote says the date assumes roughly 10% quarter-over-quarter Jemperli growth from the fourth quarter of 2025 through the second quarter of 2027 plus European dMMR rectal cancer filing and approval milestones worth $15.0 million in total[7]; meanwhile the effective rate used to accrete the balance has already been lifted from 22.7% at the end of 2024 to 33.1% at the end of 2025 and 34.9% at 31 March 2026[23], and each of those revisions is management marking down its own royalty forecast.

What to watch is therefore: the cumulative amount Sagard has received at 30 June 2026 and how far it is from $600.0 million; whether the liability fell in the period, that is whether the sweep exceeded the interest accrued; whether the effective rate was revised again and in which direction; whether the company restates, narrows or withdraws the end-of-Q2-2027 expectation now that it reports on a June fiscal year; and whether the two European milestones are still assumed inside the paydown window[24]. The falsifying observations are: a reported period in which the liability rises because accretion exceeded the sweep; the paydown date being pushed back or dropped; or the effective rate being revised upward again.

After the spin-off Anaptys says it runs on fewer than about ten contractors, less than $10 million of annualised operating expense and an EBIT margin above 95%. Once the departed biopharma costs are stripped out, does this report show that cost base, and has any of the $100.0 million repurchase authorisation been used?

The post-spin cost base matters because, until royalty cash comes back to the company, the balance sheet is the only thing paying for it. A fixed overhead of under $10 million a year against a royalty stream of this size is what makes the structure work[5]; an overhead several times larger would quietly consume the cash the repurchase programme is supposed to return[6]. This is also the first reporting period in which the question can be asked at all, because every prior quarter still carried the research programmes that left on 20 April 2026.

The figures on hand do not answer it yet. Total operating expenses were $60.2 million in the first quarter of 2026, split between $34.0 million of research and development and $26.2 million of general and administrative, and the company attributed the increase in general and administrative mainly to separation legal costs, the ongoing GSK litigation and stock compensation for two departed officers[12]. Those figures still include First Tracks, and the company said it expects to reclassify that business as discontinued operations from the second quarter. Cash and investments were $286.5 million at 31 March 2026, but measured before the separation[21], against post-spin guidance of an initial ~$140-$145 million[6]. No repurchases were made in the quarter, the 2025 programme expired unused on 31 March 2026, and the full $100.0 million of the new authorisation remained available[25].

The opposing reading is that the clean cost base arrives later than the plan suggests: separation and litigation legal work continues, the company was still searching for a chief financial officer when the plan was announced, and Anaptys remains the responsible party under the master lease on roughly 45,057 square feet, on a sublease to First Tracks that the subtenant can end with three months notice[18]. What to watch is whether First Tracks is presented as discontinued operations and what the continuing-operations expense line is once it is; the annualised run rate implied by the post-spin stub against the stated plan of less than $10 million; whether cash and investments measured after the separation land in the guided ~$140-$145 million range; whether any shares were repurchased under the authorisation that expires on 31 December 2026; and whether litigation legal costs are disclosed separately from ordinary overhead. The falsifiers are a post-spin period annualising above $12.5 million of operating expense with no disclosed one-off cause; cash materially below the guided range without repurchases to explain it; or the authorisation lapsing at the end of 2026 unused, as the prior programme did in March 2026.

Anaptys is suing GSK's Tesaro unit in the Delaware Court of Chancery over exclusivity and commercially-reasonable-efforts duties in the original collaboration agreement. Trial finished in July 2026; does this report show the case still running to the filed 20 October argument date, or has the dispute started to touch what Anaptys actually books?

This case matters more than an ordinary contract dispute because the Jemperli royalty is not an asset Anaptys controls; it is a set of contractual promises made by a licensee that also sells competing and successor oncology products. The case asks the court to declare what those promises require, which makes it the one event that can change the size and durability of nearly all of the company's revenue, and it is also why general and administrative expense has been running far above the fixed overhead the post-spin model describes[12].

The procedural facts are clear. Anaptys filed its complaint on 20 November 2025 seeking a declaration that Tesaro materially breached the collaboration agreement and that its parent GSK tortiously interfered with it[27]; Tesaro's counterclaim that Anaptys had breached its own duties was dismissed by the Delaware Court of Chancery on 24 April 2026[29]; trial of the consolidated case was held from 14 to 17 July 2026[30]; and on 28 July the court set the post-trial schedule, with answering briefs due 25 September 2026, reply briefs 9 October and argument on 20 October 2026[31]. The money has not stopped during the dispute: $258.0 million of milestones had been recognised under the agreement through 31 March 2026, with $15.0 million that may be recognised in the future[24].

The alternative reading is that nothing in the reported numbers will settle this: there is no accrual for the claim, the legal spend is bundled inside a general and administrative line that also carries separation costs and stock compensation, and a Chancery decision after argument can take months, so the report may show only that the timetable held. What to watch is whether the legal proceedings note repeats the 20 October 2026 argument date or discloses a change; whether general and administrative expense falls now that trial work is finished and the separation is complete; whether any royalty or milestone due under the GSK agreement was withheld or disputed during the period; and whether the company discloses a settlement posture or a change in the remedies it seeks. The falsifiers are a ruling that no exclusivity or diligence duty was breached, leaving the royalty unchanged and the litigation spend a pure cost; milestone or royalty payments being suspended while the case is pending; or the 20 October 2026 argument date moving materially.

Risks and Falsifiers

The first risk is competition and pricing. Jemperli competes with Keytruda, and Anaptys itself warns that Keytruda sales are expected to be materially hurt by biosimilar competition between 2028 and 2029, with European exclusivity lost in 2031[26]. Cheap checkpoint inhibitors would press Jemperli pricing exactly in the years the royalty is supposed to reach the higher 20% and 25% tiers[10], and the company's statement that it expects more than $390 million of annualised royalties as early as 2029 rests on GSK reaching peak sales of more than $2.7 billion and therefore triggering those top tiers[28]. The observation that would falsify the concern is Jemperli net sales continuing to grow at double digits through 2029 after biosimilar checkpoint inhibitors reach the market, which would show the pricing link is weaker than the risk factor implies.

The second risk is that the second royalty is much smaller than it looks from the outside. The separation agreement allocated all $35.0 million of Vanda milestones to First Tracks and left Anaptys only a 10% royalty on future net sales in generalized pustular psoriasis, a rare indication[16]; the product has a 12 December 2026 FDA target action date and no approved sales[17]. Anaptys recognising a Vanda milestone in a future period would show the allocation is not as complete as the filing describes.

The third risk is single-product, single-licensee concentration. Jemperli royalties and milestones were $221.0 million of the $234.6 million of 2025 collaboration revenue[19][20], so a slowdown at GSK passes straight to substantially all of the company's revenue, and the royalty term runs only to the later of twelve years from first commercial sale or the last patent to expire[10]. The falsifier is a reported period in which Jemperli net sales decline year over year while Anaptys still reports royalty growth, which would show the exposure is not one-for-one.

The fourth risk is the paydown schedule itself. If Jemperli growth undershoots the roughly 10% quarter-over-quarter path the schedule assumes, or the two European milestones slip, the crossover into cash royalties moves out and the company must fund several more quarters of costs and any buyback entirely from its own balance sheet[7]. On the company's first-quarter estimate, about $325 million of the $600.0 million cap was still outstanding[11], accreting at a 34.9% effective rate[23]. Conversely, a reported period in which the sweep exceeds the assumed pace and the company brings the paydown date forward would show the schedule had slack in it.

The fifth risk is that the fixed overhead is not easy to flex. While it still carries the Wateridge Circle master lease and an active Chancery case, the company is committed to spending it cannot easily reduce, and an overrun is paid for out of the same balance sheet that funds the repurchase programme[18]. Guided post-spin net cash of roughly $140-$145 million[6] has to carry both a $100.0 million repurchase authorisation[25] and a stated plan of less than $10 million of annual operating expense[5]. A post-spin period in which operating expense annualises below $10 million while the company also repurchases stock would show both commitments can be met at once.

The sixth risk is that the litigation outcome is binary and its timing is outside the company's control. A decision cannot arrive before the 20 October 2026 argument and a Chancery ruling can follow months later[31], and during that time Anaptys keeps paying legal costs out of the same balance sheet meant to fund repurchases - general and administrative expense was $26.2 million in the first quarter of 2026[12] against a post-spin plan of less than $10 million of total annualised operating expense[5]. A ruling or a disclosed settlement before the next report would remove the timing risk and attach a definite amount to the claim.

What to Watch Next

• Royalty recognition: against a baseline of $24.6 million of royalty on $313 million of GSK net sales, an implied rate near 8%[4][9], watch whether both figures are disclosed for the same months, how large the true-up is, and where cumulative calendar-year sales stood at 30 June 2026. Confirmation is an implied rate still at 8% moving with net sales; falsification is royalty growth against flat or falling net sales, or a true-up above a tenth of the line.
• Sagard sweep and cash crossover: against cumulative receipts of $249.3 million toward the $600.0 million cap and a $240.8 million Jemperli liability at 31 March 2026[11][22], watch the 30 June cumulative figure, whether the liability fell, and whether the effective rate was revised. Confirmation is a falling liability with the end-of-Q2-2027 date intact; falsification is a rising liability or a later date.
• Post-spin cost base: against first-quarter operating expenses of $60.2 million including $34.0 million of research and development[12], watch whether First Tracks is shown as discontinued operations and what the continuing expense line then is. Confirmation is an annualised run rate below $10 million; falsification is above $12.5 million with no disclosed one-off cause.
• Capital return and cash: against a $100.0 million authorisation entirely unused and guided net cash of roughly $140-$145 million[25][6], watch whether any stock was repurchased and where post-separation cash lands. Confirmation is repurchases with cash inside the guided range; falsification is the authorisation lapsing unused at the end of 2026.
• GSK collaboration litigation: against argument set for 20 October 2026 and general and administrative expense of $26.2 million[31][12], watch whether the note repeats that date, whether overhead falls, and whether any payment was withheld. Confirmation is an unchanged timetable, lower overhead and payments continuing; falsification is a material change of date or a suspended payment.

Conclusion

Anaptys today is the holder of a contract. Its revenue is GSK's Jemperli sales multiplied by a tiered percentage, $24.6 million in the first quarter of 2026 against $313 million of reported sales at the 8% first tier[4][9], and because there is no cost of revenue every dollar of royalty falls to gross profit in principle[10]. None of that money reaches the company yet: Sagard had received $249.3 million of the $600.0 million cap at 31 March 2026[11], every royalty is swept away until the cap is filled, and the unpaid balance is still accreting non-cash interest at a 34.9% effective rate[23]. The genuinely unresolved relationship sits exactly there - between the size of the royalty on the income statement and the cash the company can actually use, separated by a timeline set by the speed of the sweep rather than by how well Jemperli sells.

Two independent commentaries published after the results point at opposite ends of that timeline. Writing the day after the separation completed, Inelegant Investor at Stock Spinoffs described the remaining Anaptys as essentially a securitised royalty vehicle centred on one drug and cited Reuters that Jemperli royalty payments are expected to continue at least until key patents expire in 2035 in the United States and 2036 in the European Union[32]. Biotech Distilled, publishing the day the post-trial schedule was granted, addressed the other end, arguing that although the four-day trial finished in mid-July no ruling can come before the 20 October argument, so the earliest realistic decision window is late in the fourth quarter of 2026 and a slip into the first half of 2027 would be entirely normal[33]. The two do not conflict, and together they tighten the question: the first turns the years in which Anaptys actually keeps the royalty into a countable window running from the end of the Sagard sweep to patent expiry, while the second establishes that the legal event defining one edge of that window will not be revealed in this report. Both are outside interpretations, not facts and not a vote.

What would materially strengthen the current understanding is a combination of operating and financial observations arriving together: a transition report that discloses January-to-June Jemperli net sales alongside the royalty recognised, so the 8% arithmetic can be checked directly; cumulative Sagard receipts moving toward $600.0 million with the liability genuinely lower over the period, showing the sweep exceeded accretion; and, once First Tracks is shown as discontinued operations, a continuing-operations expense line that really does annualise below $10 million while the $100.0 million repurchase authorisation is actually used[25]. Conversely, a liability that rises because accretion exceeded the sweep, an end-of-Q2-2027 expectation that is narrowed or withdrawn, or a post-spin expense run rate still above $12.5 million with no one-off cause would each force a fresh look at whether the structure works as described.

Sources

[1] ANAB earnings calendar entry dated 2026-09-23, calendar last updated 2026-09-17 · 2026-09-17 · earnings calendar

[2] ANAB 8-K filed 2026-05-21 (change in fiscal year-end) · 2026-05-21 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526234419/anab-20260518.htm

[3] ANAB 8-K filed 2026-05-12 (Q1 2026 results) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[4] ANAB 10-Q filed 2026-05-12 (Q1 royalty revenue and non-cash interest) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[5] ANAB 8-K filed 2026-03-27 (post spin-off cost model) · 2026-03-27 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/

[6] ANAB 8-K filed 2026-03-27 (repurchase plan and post-spin net cash) · 2026-03-27 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526127783/

[7] ANAB 8-K filed 2026-05-12 (Sagard accrual and remaining paydown) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[8] Investing.com pre-earnings consensus published 2026-08-16 · 2026-08-16 · Investing.com · https://in.investing.com/news/earnings/anaptysbio-earnings-ahead-first-results-as-royalty-company-93CH-5558734

[9] ANAB 8-K filed 2026-05-12 (Jemperli Q1 2026 net sales) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[10] ANAB 10-K filed 2026-03-03 (Jemperli royalty tiers) · 2026-03-03 · 10-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/

[11] ANAB 10-Q filed 2026-05-12 (Sagard threshold and cumulative receipts) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[12] ANAB 8-K filed 2026-05-12 (Q1 2026 operating expenses) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[13] ANAB 10-K filed 2026-03-03 · 2026-03-03 · 10-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/

[14] ANAB 8-K/A filed 2026-04-24 (spin-off completion) · 2026-04-24 · 8-K/A · https://www.sec.gov/Archives/edgar/data/1370053/000119312526177317/

[15] ANAB 8-K filed 2026-04-20 (separation and distribution agreement) · 2026-04-20 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526164330/

[16] ANAB 10-Q filed 2026-05-12 (Vanda royalty retained, milestones allocated to First Tracks) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[17] ANAB 8-K filed 2026-05-12 (imsidolimab PDUFA date) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[18] ANAB 8-K filed 2026-06-22 (sublease of headquarters to First Tracks) · 2026-06-22 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526277505/anab-20260615.htm

[19] ANAB 10-K filed 2026-03-03 (FY2025 royalty revenue and non-cash interest) · 2026-03-03 · 10-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/

[20] ANAB 10-K filed 2026-03-03 (FY2025 sales milestones) · 2026-03-03 · 10-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/

[21] ANAB 10-Q filed 2026-05-12 (liquidity and funding sources) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[22] ANAB 10-Q filed 2026-05-12 (royalty liability rollforward) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[23] ANAB 10-Q filed 2026-05-12 (effective interest rate) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[24] ANAB 10-Q filed 2026-05-12 (GSK milestones recognized and remaining) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[25] ANAB 10-Q filed 2026-05-12 (stock repurchase programs) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[26] ANAB 10-Q filed 2026-05-12 (Keytruda biosimilar exposure) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[27] ANAB 10-K filed 2026-03-03 (Tesaro and GSK litigation) · 2026-03-03 · 10-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526088290/

[28] ANAB 8-K filed 2026-05-12 (long-term royalty expectation) · 2026-05-12 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219500/anab-ex99_1.htm

[29] ANAB 10-Q filed 2026-05-12 (Tesaro counterclaim dismissed) · 2026-05-12 · 10-Q · https://www.sec.gov/Archives/edgar/data/1370053/000119312526219515/anab-20260331.htm

[30] ANAB 8-K filed 2026-07-30 (trial held) · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/anab-20260728.htm

[31] ANAB 8-K filed 2026-07-30 (post-trial briefing schedule) · 2026-07-30 · 8-K · https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/anab-20260728.htm

[32] Stock Spinoffs commentary published 2026-05-21 · 2026-05-21 · Stock Spinoffs · https://www.stockspinoffs.com/2026/05/21/anaptysbio-first-tracks-spinoff-completed/

[33] Biotech Distilled commentary published 2026-07-30 · 2026-07-30 · Biotech Distilled · https://biotechdistilled.substack.com/p/update-anaptysbio-anab-the-gavel